Bavarian Nordic Seeks Critical EU Approval for Mpox Vaccine in Adolescents Aged 12 to 17

Aug 16, 2024, 11:04 AM

Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents aged 12 to 17. This move follows the World Health Organization's declaration of a global public health emergency due to a surge in mpox cases. CEO Paul Chaplin emphasized the importance of this approval, describing it as 'critical' for addressing the health crisis.